Synapse - Howard Scher

Results (1133)

Evaluating treatment tolerability using the toxicity index with patient-reported outcomes data

Journal Article

Langlais, B.; Mazza, G. L.; Thanarajasingam, G.; Rogak, L. J.; Ginos, B.; Heon, N.; Scher, H. I.; Schwab, G.; Ganz, P. A.; Basch, E.; more...
Journal of Pain and Symptom Management (2022)

Fulltext@MSK | Save

Correlation between imaging-based intermediate endpoints and overall survival in men with metastatic castration-resistant prostate cancer: Analysis of 28 randomized trials using the Prostate Cancer Clinical Trials Working Group (PCWG2) criteria in 16,511 patients

Journal Article

Woo, S.; Suh, C. H.; Wibmer, A. G.; Becker, A. S.; Teo, M. Y.; Gönen, M.; Hricak, H.; Scher, H. I.; Morris, M. J.; Vargas, H. A.
Clinical Genitourinary Cancer (2022)

Fulltext@MSK | Save

Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors

Journal Article

Stopsack, K. H.; Nandakumar, S.; Arora, K.; Nguyen, B.; Vasselman, S. E.; Nweji, B.; McBride, S. M.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; more...
Clinical Cancer Research (2022)

Fulltext@MSK | Save

Schlafen 11 (SLFN11), a putative predictive biomarker of platinum/PARPi response, is frequently detected on circulating tumor cells (CTCs) in advanced prostate cancer

Meeting Abstract

Scher, H. I.; Fernandez, L.; Cunningham, K.; Elphick, N.; Barnett, E.; Lee, J.; Gilbertson, C.; Carbone, E.; Bourdon, D.; Blankfard, M.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Interim results of AASUR: A single arm, multi-center phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA plus P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa)

Meeting Abstract

McBride, S. M.; Spratt, D. E.; Kollmeier, M.; Abida, W.; Xiao, H.; Slovin, S. F.; Paller, C. J.; Deville, C.; Den, R. B.; Hearn, J. W. D.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Quantification of metastatic prostate cancer whole-body tumor burden with (18)F-FDG PET parameters and associations with overall survival after first-line abiraterone or enzalutamide: A single-center retrospective cohort study

Journal Article

Wibmer, A. G.; Morris, M. J.; Gonen, M.; Zheng, J.; Hricak, H.; Larson, S.; Scher, H. I.; Vargas, H. A.
Journal of Nuclear Medicine (2021)

Fulltext@MSK | Save

Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy

Journal Article

Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Shevrin, D. H.; Stein, M. N.; Vaishampayan, U. N.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; Tagawa, S. T.; more...
European Urology Open Science (2021)

Fulltext@MSK | Save

Biochemical response (PSA0) and testosterone (T) recovery in Metacure, a multi-arm multi-modality (MM) therapy (tx) for very high risk localized (HRL) and low volume metastatic (LVM) prostatic adenocarcinoma

Meeting Abstract

Teo, M. Y.; McBride, S.; Gopalan, A.; Benoliel, H.; Eastham, J. A.; Goh, A.; Szmulewitz, R.; Morgans, A. K.; Bubley, G.; Gupta, S.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Chromosomal instability (CIN) biomarker in circulating tumor cells (CTC) may predict for therapy resistance in metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Keegan, N. M.; Schonhoft, J.; Barnett, E.; Cohn, E. D.; Zhao, J. L.; Carbone, E. A.; Zanone, M. R.; Anderson, A.; Wenstrup, R.; Scher, H. I.
Annals of Oncology (2021)

Fulltext@MSK | Save

Prospective evaluation of clinical outcomes using a multiplex liquid biopsy targeting diverse resistance mechanisms in metastatic prostate cancer

Journal Article

Sperger, J. M.; Emamekhoo, H.; McKay, R. R.; Stahlfeld, C. N.; Singh, A.; Chen, X. E.; Kwak, L.; Gilsdorf, C. S.; Wolfe, S. K.; Wei, X. X.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save